The Department of Hematology at the First Affiliated Hospital of Chongqing Medical University was established in 1956 and stands as one of the largest hematology specialties in Southwest China, integrating medical care, education, and research. It has received several prestigious recognitions, including being designated as a National Clinical Key Specialty Construction Project, a National Clinical Drug Trial (GCP) base, and one of the first members of the China Hematology Specialist Alliance. The department also serves as the Hematopoietic Stem Cell Transplantation Training Base for Chongqing, the Chongqing Stem Cell Collection and Transplantation Center for the Chinese Marrow Donor Program, the key specialty of the Chongqing Municipal Education Commission, and the Hematopoietic Stem Cell Transplantation Center of Chongqing Medical University.
The department has 121 available beds, including 15 rooms equipped with advanced facilities in a Class 100 laminar flow ward. Annually, it admits approximately 4,000 inpatients, primarily treating hematologic malignancies such as leukemia, myelodysplastic syndrome (MDS), lymphoma, and myeloma. The department's comprehensive treatment capabilities have reached the advanced domestic and international levels. With a robust research foundation, the department is involved in numerous national and municipal research projects. In the past five years, the department has published nearly 100 research papers, 63 papers published in SCI-indexed journals, with the highest impact factor exceeding 20. The department has been awarded the Third Prize of Chongqing Science and Technology Progress Award, holds several invention patents, and has participated in formulating more than 10 industry guidelines and consensus documents. The primary research focuses include basic and clinical studies on hematopoietic stem cell transplantation, the molecular mechanisms underlying hematologic malignancies, and the diagnosis and treatment of difficult and complicated hematologic diseases.